All Blogs
Jun 26, 2026
TRODELVY’s First-Line TNBC Approval: Gilead’s Big Bet Reshapes the TROP2 ADC Battlefield
Summary TRODELVY redefines first-line mTNBC treatment as the only approved ADC independent of PD-L1 expression. TRODELVY sets a new standard as Europe’s first ADC and first novel therapy in two decades for eligible patients with first-line metastatic triple-negative breast cancer. Approval was based on AS...
Read More...
Jun 25, 2026
Legacy Expands Diagnostic Portfolio with New York CLEP Approval for Two LDTs; Quest Diagnostics Expands Patient Access to ctDNA MRD Testing with New York Approval of Haystack MRD; MVZ MedDiagnost and Sectra Ink 10-Year Deal to Unify Radiology Network Across 10 Sites; ALZpath and Abbott Enter Global Licensing Deal to Expand Blood-Based Alzheimer’s Diagnostics; Corvention Reaches Key Commercial Milestone with First U.S. Procedure and Balloon Catheter Launch; ZETA SURGICAL® Achieves First Clinical Milestone with Initial Patient Treatment at HOPE Therapeutics
Legacy Received New York State CLEP Approval for Two Laboratory-Developed Tests: Semen Analysis and DNA Fragmentation On 24 June 2026, Legacy announced that the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP), administered by the Wadsworth Center, had validated and approved it...
Read More...
Jun 24, 2026
Fusion Biopsy: The Next Generation of Prostate Cancer Detection
Prostate cancer remains the second most common malignancy diagnosed in men worldwide, with global incidence now exceeding 1.4 million new prostate cancer cases a year. For decades, the diagnostic pathway leaned on a blunt instrument: a 12-core systematic biopsy taken largely by anatomical guesswork. That era is clo...
Read More...
Jun 23, 2026
Definium Reports Positive Phase 3 EMERGE Results for DT120 ODT in MDD; AbbVie to Buy Apogee Therapeutics; TrueLab Announces Strategic Antibody Licensing Collaboration with Bionyra Pharma; Nura Bio Secures Series B Financing to Advance SARM1 Programs; Moderna’s mRNA-1010 Earns Unanimous FDA Advisory Committee Backing on Benefit-Risk Profile
Definium Therapeutics Advances DT120 ODT with Positive Results from Pivotal Phase 3 EMERGE Study Definium Therapeutics, Inc. reported positive topline findings from Emerge, its first Phase 3 randomized, double-blind, placebo-controlled trial assessing a single 100 µg dose of DT120 (lysergide) orally disintegrati...
Read More...
Jun 22, 2026
EGFR-Mutant NSCLC: From Targeted Therapy Breakthroughs to the Next Era of Precision Medicine
Summary Non-small cell lung cancer accounts for ~85% of all lung cancer cases, with incidence rising steadily. The EGFR-mutant NSCLC landscape has progressed from 1st/2nd-generation EGFR TKIs (limited by T790M resistance, poor CNS penetration, and toxicity) to more effective 3rd-generation TKIs, with osimert...
Read More...
Jun 19, 2026
Navigating the Future of Biliary Tract Cancer Treatment: Precision Oncology and Emerging Therapeutic Strategies
Summary The BTC treatment landscape is shifting from chemotherapy to precision oncology. While gemcitabine-based chemotherapy remains the backbone of first-line and advanced disease treatment, the field has increasingly moved toward biomarker-driven therapy and chemoimmunotherapy. Approved targeted therapies...
Read More...
Jun 18, 2026
FiberSense CGM System Secures CE Mark; AMDI™ Fast PCR System Achieves FDA 510(k) Clearance and CLIA Waiver for Near-Patient Respiratory Diagnostics; Icarus Medical Raises $7.2 Million Series A to Drive Next-Phase Growth; Crescom and Mass General Brigham Launch Global Proof of Concept for Pediatric Musculoskeletal AI; VahatiCor Reaches Key Milestone with First U.S. Patient Dosed in SERRA-I CMD Study; Sonex Health Unveils Results From Largest-Ever U.S. Investigation of UltraGuideCTR™
FiberSense Continuous Glucose Monitoring (CGM) System obtains CE mark as commercial launch preparations begin On 17 June 2026, FiberSense AG announced that its FiberSense Continuous Glucose Monitoring (CGM) System had received CE marking under Regulation (EU) 2017/745 as a Class IIb medical device. T...
Read More...
Jun 17, 2026
Mapping the Mind: How Neurodiagnostics Is Redefining the Future of Brain Healthcare
The human brain, only three pounds of tissue, remains one of medicine's greatest frontiers. As neurological disorders emerge as the world's leading cause of disability, the tools we use to diagnose, monitor, and understand brain health have never been more consequential. Neurodiagnostics, encompassing the ful...
Read More...
Jun 16, 2026
Ultomiris Receives US Priority Review for Adult IgA Nephropathy Treatment; FDA Approves WELIREG Plus KEYTRUDA or KEYTRUDA QLEX for Adjuvant Treatment of Select ccRCC Patients; Jazz Pharmaceuticals Highlights Phase 3 LAGOON Trial Update for Zepzelca® in Second-Line SCLC; Novartis’ delpacibart braxlosiran (del-brax) Achieves Primary Biomarker Endpoint in Phase I/II FSHD Study; Takeda’s Zasocitinib Tops Deucravacitinib in Phase 3 Psoriasis Trial, Setting a New Benchmark for Oral Therapies; IMAAVY Demonstrates Clinically Meaningful and Sustained Hemoglobin Responses in Pivotal wAIHA Study
Ultomiris Secures Priority Review Status in the US for Adult IgA Nephropathy Alexion, AstraZeneca Rare Disease announced that the FDA has accepted and granted Priority Review to the supplemental Biologics License Application (sBLA) for Ultomiris as a potential treatment for adults with Immunoglobulin A Nephropat...
Read More...
Jun 15, 2026
The Oral GLP-1 Revolution: How Pill-Based Drugs Are Reshaping the Obesity Treatment Space
Summary The obesity drug landscape is shifting from injectable GLP-1s to oral pill-based treatments, marking a major turning point in pharmacotherapy. Two oral GLP-1s have now received FDA approval: Novo Nordisk's WEGOVY pill (December 2025) and Eli Lilly's FOUNDAYO (April 2026). Several companies, such a...
Read More...